Piper Jaffray analyst William Quirk views Oxford Immunotec's (OXFD) patent infringement lawsuit against QIAGEN (QGEN), Quest Diagnostics (DGX) and LabCorp (LH) as a surprise since QIAGEN's QuantiFERON-TB Gold and QuantiFERON-TB Plus tests have been on the market for over eight years. If Oxford were to win the suit, the most likely outcome is a royalty payment on every QuantiFERON test, Quirk tells investors in a research note. He points out that patent suits typically last two-to-three years, however. The analyst has an Overweight rating on Oxford Immunotec with a $29 price target

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here

Quest Diagnostics announced the launch of a new blood biomarker test for phosphorylated tau 217, or p-tau217. P-tau217 is a biomarker associated with Alzheimer's Disease, supported by research as useful for an early diagnosis of AD. The test is the latest addition to the AD-Detect portfolio of blood tests for assessing the risk of Alzheimer's Disease, which also includes testing for an array of AD biomarkers, including p-tau181 and amyloid beta proteins, as well as Apolipoprotein E isoform and plasma testing, for patients with cognitive impairment. The test is expected to be available for ordering on April 26.